Skip to content

MDMA for anxiety: all studies

Page 10 of 10: studies 91 to 95 of 95, newest first. Back to the MDMA for anxiety overview

Research

No Difference in Brain Activation During Cognitive Performance Between Ecstasy (3,4-Methylenedioxymethamphetamine) Users and Control Subjects: A [H215O]-Positron Emission Tomography Study

Journal of Clinical Psychopharmacology February 1, 2001 Alex Gamma, Alfred Buck, Thomas Berthold et al. 84 citations

The long-term use of the serotonin-releaser and uptake-inhibitor 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") has been associated with memory impairments and increased liability to depressive mood and anxiety attacks. It is unclear, however, whether these psychologic deviations are reflected in alterations of the underlying neurophysiologic substrate. The authors compared mood and...

Mood state and brain electric activity in Ecstasy users

Neuroreport 2000 Alex Gamma, Edi Frei, Dietrich Lehmann et al. 81 citations

Resting EEG during open and closed eyes and subsequent mood ratings were obtained from 15 Ecstasy users and 14 Ecstasy-naive controls. Absolute spectral power on the scalp, and the three-dimensional, intracerebral distribution of neuroelectric activity using low resolution brain electromagnetic tomography (LORETA) were computed. LORETA revealed global increases of theta, alpha 1 and beta 2/3...

MDMA ("ecstasy") and panic disorder: induction by a single dose.

Biological Psychiatry November 15, 1992 Una D. Mccann, George A. Ricaurte

( +_ )3,4-Methylenedioxymethamphetamine (MDMA) is a synthetic amphetamine analogue used recreationally by humans in the United States (Pcroutka 1987) and Western Europe (Anon 1992), and is thought by some to have potential utility as a psychotherapoutic adjunct (Grinspoon and Bakalar 1986). It is generally believed that MDMA acts via central monoamines, primariJy by inducing transmitter release...

MDMA (Ecstasy) precipitation of panic disorder.

Biological Psychiatry July 1, 1992 S Pallanti, D Mazzi

The authors describe three patients whose panic disorder began during recreational use of MDMA (Ecstasy) and was subsequently complicated by agoraphobic avoidance that continued autonomously after cessation of the drug. Their panic disorder responded well to serotoninergic antidepressant drugs. Theoretical and practical implications are discussed.

Utilizing In Vivo and Imaginal Exposure in the Context of MDMA-Assisted Therapy for Social Anxiety Disorder: A Case Report

Jason B. Luoma, M. Kati Lear, Kyong Yi et al. preprint

This case report describes the application of in vivo and imaginal exposure techniqueswithin MDMA-assisted therapy (MDMA-AT) for social anxiety disorder (SAD). The treatment,conducted as part of a randomized controlled trial, consisted of three non-drug preparationsessions, two drug sessions, and six non-drug integration sessions. Exposure interventionsincluded imaginal exposure to...